New hope for Tough-to-Treat lymphoma: targeted drug trial seeks better results
NCT ID NCT06846463
Summary
This study is testing whether adding the targeted drug zanubrutinib to standard chemotherapy (R-CHOP) works better for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who have specific genetic markers. The trial will enroll about 21 adults with these markers to see if the combination leads to more complete remissions and keeps the cancer from returning for longer. Researchers will monitor patients for two years to measure the treatment's effectiveness and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.